With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway
Johnson & Johnson investors are turning attention to 2023, when the company's top-selling drug is set to face biosimilar competition in the US for the first time.
You may also be interested in...
The company's 2023 revenue guidance calls for 4.5%-5.5% growth, taking into account ongoing macroeconomic uncertainty and inflationary pressures.
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.